Canada Life’s Y-mAbs Therapeutics YMAB Stock Holding History

Canada Life’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,048	Closed	-$24K	–	2021
2024 Q4	$24K	Hold	3,048	–	–	﹤0.01%	1948
2024 Q3	$40K	Hold	3,048	–	–	﹤0.01%	1965
2024 Q2	$37K	Buy	+3,048	New	+$41.1K	﹤0.01%	1993
2023 Q1	–	Sell	-1,443	Closed	-$7K	–	2334
2022 Q4	$7K	Hold	1,443	–	–	﹤0.01%	2339
2022 Q3	$21K	Hold	1,443	–	–	﹤0.01%	2258
2022 Q2	$22K	Hold	1,443	–	–	﹤0.01%	2247
2022 Q1	$18K	Hold	1,443	–	–	﹤0.01%	2377
2021 Q4	$23K	Hold	1,443	–	–	﹤0.01%	2351
2021 Q3	$41K	Hold	1,443	–	–	﹤0.01%	2283
2021 Q2	$49K	Hold	1,443	–	–	﹤0.01%	2281
2021 Q1	$43K	Hold	1,443	–	–	﹤0.01%	2338
2020 Q4	$71K	Hold	1,443	–	–	﹤0.01%	2181
2020 Q3	$55K	Hold	1,443	–	–	﹤0.01%	2156
2020 Q2	$62K	Hold	1,443	–	–	﹤0.01%	2171
2020 Q1	$38K	Hold	1,443	–	–	﹤0.01%	2212
2019 Q4	$45K	Buy	+1,443	New	+$42.7K	﹤0.01%	2300
2019 Q3	–	Sell	-1,383	Closed	-$32K	–	2314
2019 Q2	$32K	Buy	+1,383	New	+$31.8K	﹤0.01%	2529

Other funds holding YMAB

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Canada Life's YMAB Position: Q1 2025 in Review

Canada Life sold out of Y-mAbs Therapeutics (YMAB) in Q1 2025, closing a stake of 3,048 shares — an estimated $24K sold.

Canada Life first reported a position in YMAB in Q2 2019 and held it in 17 quarters. The position peaked at $71K in Q4 2020. 102 funds tracked by Wall St. Rank hold YMAB as of Q1 2025.

Canada Life reported no remaining Y-mAbs Therapeutics position as of Q1 2025 after selling out during the quarter.
Canada Life sold 3,048 Y-mAbs Therapeutics shares in Q1 2025, an estimated $24K.
Canada Life first reported a position in Y-mAbs Therapeutics in Q2 2019 and held it in 17 quarters.
Canada Life's Y-mAbs Therapeutics position peaked at $71K in Q4 2020.
102 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2025.

Based on Canada Life's 13F filing for Q1 2025, filed 15 May 2025.